Mereo BioPharma Group plc Director Dealing (1507V)

TIDMMPH

RNS Number : 1507V

Mereo BioPharma Group plc

05 August 2020

Mereo BioPharma Group plc

Notification of Director Dealing

London and Redwood City, Calif ., August 5, 2020 - Mereo BioPharma Group plc (NASDAQ: MREO, AIM: MPH), "Mereo" or "the Company", a clinical-stage biopharmaceutical company focused on oncology and rare diseases, received notification that on July 31 2020 Denise Scots-Knight, Chief Executive Officer of Mereo, purchased 10,563 American Depositary Shares (ADSs) at a price of USD 2.85 per ADS.

The below announcement and notification is made in accordance with the EU Market Abuse Regulation. The form required under the EU Market Abuse Regulation follows.

 
 1    Details of the person discharging managerial responsibilities 
 a)   Name                      Denise Scots-Knight 
     ------------------------  ---------------------------------------------- 
 2    Reason for the notification 
     ------------------------------------------------------------------------ 
 a)   Position/status           Chief Executive Officer 
     ------------------------  ---------------------------------------------- 
 b)   Initial notification/     Initial notification 
       Amendment 
     ------------------------  ---------------------------------------------- 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ------------------------------------------------------------------------ 
 a)   Name                      Mereo BioPharma Group plc 
     ------------------------  ---------------------------------------------- 
 b)   LEI                       213800U8JQHIJOS5AS09 
     ------------------------  ---------------------------------------------- 
 4    Details of the transaction(s): section to be repeated for 
       (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions have 
       been conducted 
     ------------------------------------------------------------------------ 
 a)   Description of            MEREO BIOPHARMA GROUP PLC AMERICAN DEPOSITARY 
       the financial             SHARES (ADSs) 
       instrument, type 
       of instrument 
       and identification 
       code 
     ------------------------  ---------------------------------------------- 
 b)   Nature of the             PURCHASE 
       transaction 
     ------------------------  ---------------------------------------------- 
 c)   Price(s) and                Price(s)    Volume(s) 
       volume(s)                   USD 2.85    10,563 
                                              ---------- 
     ------------------------  ---------------------------------------------- 
 d)   Aggregated information: 
       volume, Price 
     ------------------------  ---------------------------------------------- 
 e)   Date of the transaction   2020-07-31 
     ------------------------  ---------------------------------------------- 
 f)   Place of the              XNMS 
       transaction 
     ------------------------  ---------------------------------------------- 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHLZLLBBVLZBBK

(END) Dow Jones Newswires

August 05, 2020 02:00 ET (06:00 GMT)